<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-09T17:13:00Z</responseDate>
  <request identifier="oai:figshare.com:article/34002666" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34002666</identifier>
        <datestamp>2026-09-26T10:14:07Z</datestamp>
        <setSpec>category_24781</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;b&gt;Serum metabolites identification: characterizing the metabolic landscape&lt;/b&gt;</dc:title>
          <dc:creator>Ying Zou (18877177)</dc:creator>
          <dc:subject>Cancer diagnosis</dc:subject>
          <dc:subject>cervical cancer; metabolomics; metabolite; diagnosis; prognosis.</dc:subject>
          <dc:description>&lt;p dir="ltr"&gt;Metabolomics is a valuable tool for identifying biomarkers associated with cervical cancer (CC). However, the specific metabolic biomarkers indicative of prognosis in CC remains largely elusive. In this study, gas chromatography-mass spectrometry (GC-MS)-based metabolomics was employed to investigate metabolic alterations in 55 serum samples obtained from patients diagnosed with CC. Our findings revealed that lipid and amino acid metabolism were significantly disturbed in the serum of CC patients, particularly in the biosynthesis of unsaturated fatty acids. 2-furoic acid, 2-aminoheptanedioic acid, 2,3-dihydroxybenzoic acid, and valproic acid were effective in distinguishing early-stage from late-stage CC patients. In patients who underwent radiotherapy, notable alterations in cadaverine, arachidonic acid, ethanolamine, 2-ethylhexanoic acid and oleic acid effectively differentiated those who received radiotherapy from those who did not. For chemotherapy patients, significantly reduced levels of L-glycine, L-aspartic acid, and L-glutamic acid, could distinguish between those who did and did not receive chemotherapy. Furthermore, a risk model based on L-norvaline, palmitic acid, 2-furoic acid, 2H-1,4-benzodiazepin-2-one and L-threonine could predict the prognosis of CC. These results highlight the connection between serum metabolite levels and the occurrence and progression of CC, indicating a need for further research to clarify the specific roles of these metabolites.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-26T10:14:07Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.34002666.v1</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_b_Serum_metabolites_identification_characterizing_the_metabolic_landscape_b_/34002666</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
